Not sure if you consider me a naysayer, but just in case, here's...

Not sure if you consider me a naysayer, but just in case, here's some balance.

With respect to HER-Vaxx, I stand by all my comments and I hope that you go through with your threat to show my post to Leslie. You obviously have a relationship with her, so hopefully you can get a response and share it with the rest of us who don't seem to be able to get the same access.

With respect to PD1-Vaxx: we were told in August that recruitment would start then, subsequently the enrollment was pushed back from August to November on the clinicaltrials site and now we hear that the first three recruits have been enrolled by mid-December. While this represents a 3-month slippage, in the context of a covid environment, I think the company has done well in this regard. Not sure why people are inclined to dump into 10c on the back of this announcement as the quick turnaround in Phase 1 reporting for PD1-Vaxx means that in a few months, and on the basis of a likely safety profile, shareholders should be issued with a second lottery ticket for free.

So while the sell down from 14c to 10c - on the back of the reality of the limitations of the HER-Vaxx results to date - made sense to me, I'd be surprised if there was a further sell down now that the PD1-Vaxx trial is a reality ...